OPS is doing every move the right way !A quick review from the Q3 financial report.
Q3 2022 Q3 2021
-Sales and marketing $ 3 639 000 $ 2 316 000 +57 %
-Research and
developmnet $ 2 322 000 $ 1 590 000 +46 %
Exactely where to expense and grow the business. The FDA approval on top of the already approval by Health Canada and Europe Health to be implemented next year will grow the top line revenue.Japan is another plus to the growth revenue.
Huge potential for OPS and Big Players are taking note and a take over is possible in the coming year.
What I'm expecting : a 20% leap with the FDA stamp
.................................a 40% leap with a buy out .
This mean that the share price may be at a $ 5,00 level at the end of 2023.